Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11060-015-1875-1 http://scihub22266oqcxt.onion/10.1007/s11060-015-1875-1 26233248!ä!26233248 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26233248&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26233248.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Neurooncol 2015 ; 125 (1): 1-7 Nephropedia Template TP {{tp|p=26233248|t=2015. Current status of intratumoral therapy for glioblastoma |pdf=|usr=}}{{26233248}} gab.com Text Current status of intratumoral therapy for glioblastoma JO: J Neurooncol http://www.kidney.de/pget.php?&tw=1&pmid=26233248 #FOAvip With emerging drug delivery technologies becoming accessible, more options are expected to become available to patients with glioblastoma (GBM) in the near future. It is important for clinicians to be familiar with the underlying mechanisms and limitations of intratumoral drug delivery, and direction of recent research efforts. Tumor-adjacent brain is an extremely complex living matrix that creates challenges with normal tissue intertwining with tumor cells. For convection-enhanced delivery (CED), the role of tissue anisotropy for better predicting the biodistribution of the infusate has recently been studied. Computational predictive methods are now available to better plan CED therapy. Catheter design and placement-in addition to the agent being used-are critical components of any protocol. This paper overviews intratumoral therapies for GBM, highlighting key anatomic and physiologic perspectives, selected agents (especially immunotoxins), and some new developments such as the description of the glymphatic system. Twit Text FOAVip Current status of intratumoral therapy for glioblastoma ????J Neurooncol http://www.kidney.de/pget.php?&tw=1&pmid=26233248 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26233248 #FOAvip English Wikipedia <ref>{{Cite pmid|26233248}}</ref> Current status of intratumoral therapy for glioblastoma #MMPMID26233248 Mehta AI; Linninger A; Lesniak MS; Engelhard HH J Neurooncol 2015[Oct]; 125 (1): 1-7 PMID26233248show ga With emerging drug delivery technologies becoming accessible, more options are expected to become available to patients with glioblastoma (GBM) in the near future. It is important for clinicians to be familiar with the underlying mechanisms and limitations of intratumoral drug delivery, and direction of recent research efforts. Tumor-adjacent brain is an extremely complex living matrix that creates challenges with normal tissue intertwining with tumor cells. For convection-enhanced delivery (CED), the role of tissue anisotropy for better predicting the biodistribution of the infusate has recently been studied. Computational predictive methods are now available to better plan CED therapy. Catheter design and placement-in addition to the agent being used-are critical components of any protocol. This paper overviews intratumoral therapies for GBM, highlighting key anatomic and physiologic perspectives, selected agents (especially immunotoxins), and some new developments such as the description of the glymphatic system. |*Drug Delivery Systems/methods/trends[MESH] |Antineoplastic Agents/*therapeutic use[MESH] |Brain Neoplasms/*drug therapy[MESH] |Glioblastoma/*drug therapy[MESH]Current status of intratumoral therapy for glioblastoma (epmc).pdf DeepDyve Pubget Overpricing